Kobayashi Pharmaceutical Co., the Japanese health products company that was at the center of a supplement contamination scandal involving suspected deaths, is said to be considering a potential buyout offer of more than ¥500 billion ($3.2 billion) by private equity investors.
Kobayashi Pharmaceutical Co., the Japanese health products company that was at the center of a supplement contamination scandal involving suspected deaths, is said to be considering a potential buyout offer of more than ¥500 billion ($3.2 billion) by private equity investors.
<iframe src="https://statesidedaily.com/embed/cluster/cc8410b4e0a3b368472e46923f7688421f6da21d" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Kobayashi in $3.2 Billion Buyout Talks After Red-Yeast Case"></iframe>